Filing Analysis
Genasys Inc. filed an 8-K to announce its financial results for the fiscal quarter ended June 30, 2026. The filing serves as a formal notice that a press release containing these results was issued on August 13, 2026.
📋 Key Facts
- Reporting period: Fiscal quarter ended June 30, 2026.
- Filing date: August 13, 2026.
- The filing includes a press release (Exhibit 99.1) regarding results of operations and financial condition.
Genasys Inc. filed an 8-K to provide a press release under Item 7.01 (Regulation FD Disclosure). The filing does not contain substantive financial data or material event details within the text provided.
📋 Key Facts
- Filing date: July 30, 2026
- The company issued a press release on July 30, 2026 (Exhibit 99.1)
- Information is furnished under Item 7.01 and is not considered 'filed' for purposes of Section 18 liability.
Genasys Inc. has entered into a Third Amendment to its Term Loan and Security Agreement, extending the maturity date of its $15.2 million debt from July 2026 to July 2027. The amendment includes highly punitive terms, including a guaranteed minimum return (MOIC) of 20% for lenders and increased default interest rates.
🚩 Red Flags
- Highly punitive debt terms (20% guaranteed minimum return).
- Significant cash outflow requirement: $1 million monthly payments starting Oct 2026.
- Tight liquidity covenant of $4 million minimum liquidity.
- Increased default interest rates indicate higher risk profile for lenders.
- Warrant price reduction suggests potential dilution and downward pressure on share price.
📋 Key Facts
- Principal amount outstanding under the Term Loan is $15,206,812.50.
- Maturity date extended from July 13, 2026, to July 13, 2027.
- Lenders are guaranteed a minimum return (MOIC) of 20%.
- The Company must make monthly payments of $1 million starting October 1, 2026, covering principal and the MOIC.
- Default interest rate increased by 5% above the applicable per annum rate.
- Warrant exercise price reduced from $2.53 to $2.28 per share; exercise period extended to May 13, 2030.
Genasys Inc. entered into a $4.3 million unsecured term loan agreement with Maran Partners Fund, LP on June 9, 2026, to fund working capital and general corporate purposes.
🚩 Red Flags
- Extremely high interest rate (18%) suggests high risk or lack of access to traditional cheaper financing.
- Very short maturity window (approximately 3 months from closing to September 14, 2026), creating immediate refinancing or repayment pressure.
- Significant upfront cost: the $301,000 origination fee represents ~7% of the principal amount.
📋 Key Facts
- Principal amount of the loan is $4.3 million.
- Interest rate is 18% per annum (Fixed Rate), increasing by 5% upon an Event of Default.
- Loan maturity date is September 14, 2026 (very short-term duration).
- Company paid an upfront origination fee of $301,000.
- Exit fee ranges from $64,500 to $150,500 depending on repayment date.
- Loan is unsecured but contains restrictive negative covenants regarding distributions, indebtedness, and asset sales.
Genasys Inc. (GNSS) filed an 8-K on May 14, 2026 disclosing a Second Amendment to its Term Loan and Security Agreement with Cantor Fitzgerald Securities as agent, extending the maturity date of its term loan from May 13, 2026 to July 13, 2026 — a very short two-month extension — in exchange for a 1.0% extension fee on outstanding principal. The filing simultaneously covers quarterly financial results for the period ended March 31, 2026. The extremely short extension window raises significant refinancing and liquidity concerns for this micro-cap company.
🚩 Red Flags
- Second amendment in ~2 years signals repeated inability to refinance or repay the term loan
- Only 60-day extension granted (May 13 → July 13, 2026) — extremely short runway suggesting lender reluctance
- 1.0% extension fee on outstanding principal indicative of distress-level borrowing terms
- Restrictive covenants limit distributions, new debt, asset sales, and investments, constraining strategic flexibility
- Multiple 8-K items (1.01, 2.02, 2.03) triggered simultaneously, suggesting overlapping operational and financial pressures
- Term loan secured against company assets (collateral agent named), meaning default risk could threaten asset base
- July 13, 2026 new maturity is imminent — refinancing or repayment solution must be found within weeks
📋 Key Facts
- Term loan originally entered May 13, 2024 under Term Loan and Security Agreement with Cantor Fitzgerald Securities as administrative and collateral agent
- Second Amendment dated May 12, 2026 extends maturity from May 13, 2026 to July 13, 2026 — only a 60-day extension
- Extension fee of 1.0% of outstanding principal amount of the term loan paid to lenders
- This is the SECOND amendment, implying a prior extension was also necessary
- Loan covenants restrict Company from certain distributions, investments, indebtedness, asset sales, loans, and payments
- Subsidiaries party to the agreement include Evertel Technologies LLC, Zonehaven LLC, and Genasys Puerto Rico LLC
- Quarterly financial results for fiscal quarter ended March 31, 2026 also disclosed via press release (Exhibit 99.1)
- Filing signed by CFO Cassandra L. Hernandez-Monteon on May 14, 2026
- Company trades on NASDAQ Capital Market under ticker GNSS
- Items 1.01, 2.02, 2.03, and 9.01 all triggered in this single filing
Genasys Inc. has appointed Lawrence F. Hagenbuch to its Board of Directors and as Chairman of the Audit Committee, effective March 26, 2026. Mr. Hagenbuch brings extensive experience in financial oversight, turnaround management, and internal control enhancement from his roles at Crossplane Capital and Huron Consulting.
📋 Key Facts
- Lawrence F. Hagenbuch (age 59) was elected as a director and appointed Chairman of the Audit Committee on March 26, 2026.
- Mr. Hagenbuch currently serves as an Operating Partner at Crossplane Capital and previously held a leadership role at Huron Consulting focused on turnarounds and interim management.
- He possesses significant public company board experience, currently serving as Audit Committee Chair for HireQuest, Inc. (NASDAQ: HQI).
- The appointment includes a grant of restricted stock units (RSUs) on the same terms as other non-employee directors.
- His professional background includes operational and financial leadership roles at GE Capital, J. Hilburn, and American National Can.
Genasys Inc. reported the results of its 2026 Annual Meeting of Stockholders held on March 17, 2026. Shareholders elected five directors, ratified the company's independent auditor, and approved executive compensation on an advisory basis.
📋 Key Facts
- The meeting was held on March 17, 2026, with 25,083,917 shares represented out of 45,212,311 eligible shares.
- Five directors were elected for one-year terms: Richard S. Danforth, William H. Dodd, W. Craig Fugate, R. Rimmy Malhotra, and Susan Lee Schmeiser.
- Baker Tilly US, LLP was ratified as the independent registered public accounting firm for the fiscal year ending September 30, 2026, with 21,419,235 votes in favor.
- The advisory vote on executive compensation passed with 8,844,760 votes for and 5,107,733 votes against.
- Director Susan Lee Schmeiser received the highest 'Withheld' count among nominees with 4,044,163 withheld votes.
Genasys Inc. filed an 8-K to announce its financial results for the fiscal quarter ended December 31, 2025. The filing serves as a formal notice that a press release containing these results was issued on February 10, 2026.
📋 Key Facts
- Reported date: February 10, 2026
- Reporting period: Fiscal quarter ended December 31, 2025
- The filing includes Exhibit 99.1 (Financial Results Press Release)
- Filed under Item 2.02 (Results of Operations and Financial Condition)
Genasys Inc. announced the approval of the 2026 compensation package for CEO Richard Danforth, which includes a base salary of $490,000 and significant equity/cash incentives tied to specific performance metrics.
🚩 Red Flags
- Heavy emphasis on 'debt-repayment' as a primary metric (40% weight) for both cash bonuses and RSU vesting, suggesting the company is focused on deleveraging.
- Cancellation of 800,000 previously granted performance-based options.
📋 Key Facts
- CEO Richard Danforth's 2026 base salary is set at $490,000.
- Compensation includes a cash bonus plan with a target of 100% of base salary ($490,000).
- Grant of 200,000 time-based RSUs: 67,000 vest Dec 31, 2026; 133,000 vest Dec 31, 2027.
- Grant of 200,000 performance-based RSUs subject to meeting revenue, ARR, and debt-repayment thresholds.
- Performance metrics for bonuses/RSUs include: Revenue (30%), Annual Recurring Revenue (ARR) (30%), and Debt Repayment (40%).
- The Board canceled 800,000 performance-based options previously granted to Mr. Danforth on October 8, 2022.
Genasys Inc. announced the permanent promotion of Cassandra Hernandez-Monteon to Chief Financial Officer, Treasurer, and Secretary on December 24, 2025, following her interim tenure since July 1, 2025.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Ms. Cassandra Hernandez-Monteon promoted from Interim CFO to permanent CFO, Treasurer, and Secretary effective Dec 24, 2025.
- Base salary increased to $275,000.
- Approved bonus plan for FY2026 with payouts of 0% to 100% based on two financial and one operating performance measures.
- Granted 70,000 Restricted Stock Units (RSUs) under the 2025 Equity Incentive Plan.
- RSU structure: 35,000 units time-based vesting over 3 years; 35,000 units performance-based vesting over 3 years.
- RSUs include accelerated vesting upon a change of control.
Genasys Inc. entered into an Amended and Restated Cooperation Agreement with entities affiliated with Director R. Rimmy Malhotra, involving board nominations and interim audit committee leadership. The agreement also includes standstill restrictions and non-disparagement clauses.
🚩 Red Flags
- Related-party transaction involving a director's affiliated entities (Nicoya Capital LLC, etc.).
- Potential governance risk regarding the Audit Committee Chair position being subject to negotiation with an investor group.
- Complex board nomination structure resulting from a cooperation agreement rather than standard shareholder processes.
📋 Key Facts
- Entered into A&R Cooperation Agreement on December 19, 2025, with Nicoya Capital LLC, Nicoya Fund LLC, and Nicoya Genasys-SPV LLC.
- The Investor Parties are affiliates of Company director R. Rimmy Malhotra.
- Company to nominate five individuals (Danforth, Schmeiser, Dodd, Fugate, and Malhotra) for election at the 2026 Annual Meeting.
- Agreement includes a provision for Mr. Malhotra to serve as interim Chair of the Audit Committee if a mutually acceptable nominee is not identified by June 30, 2026.
- Investor Parties agreed to standstill restrictions and mutual non-disparagement provisions.
- Director Mark Culhane will not stand for re-election at the 2026 Annual Meeting (not due to disagreement).
Genasys Inc. announced that Chairman of the Board, Richard H. Osgood III, will not stand for re-election at the upcoming 2026 Annual Meeting of Stockholders. He will remain in his current role until the conclusion of his term.
📋 Key Facts
- Richard H. Osgood III notified the Board on December 4, 2025, that he will not seek re-election at the 2026 Annual Meeting.
- Mr. Osgood has served as a director since 2013 and as Chairman since 2021.
- The departure is not due to any disagreement with the Company regarding operations, policies, or practices.
- He will continue to serve his term until the Annual Meeting.
Genasys Inc. filed an 8-K to announce the release of its financial results for the fiscal fourth quarter and full year ended September 30, 2025.
📋 Key Facts
- Report date: December 9, 2025
- Reporting period: Fiscal fourth quarter and full year ended September 30, 2025
- The filing includes a press release (Exhibit 99.1) containing the results of operations and financial condition.
Genasys Inc. filed an 8-K to furnish its press release regarding financial results for the fiscal quarter ended June 30, 2025. This is a standard earnings announcement filing.
📋 Key Facts
- Report date: August 14, 2025
- Reporting period: Fiscal quarter ended June 30, 2025
- The filing serves to furnish Exhibit 99.1 (Financial Results Press Release)
- Signed by Cassandra L. Hernandez-Monteon, CFO
Genasys Inc. announced the retirement of its CFO, Treasurer, and Secretary, Dennis D. Klahn, effective July 1, 2025. The company has appointed Cassandra Hernandez-Monteon as interim CFO to manage the transition.
🚩 Red Flags
- Sudden transition to interim leadership for a critical C-suite role (CFO).
📋 Key Facts
- Dennis D. Klahn retired from his roles as CFO, Treasurer, and Secretary on July 1, 2025.
- Cassandra Hernandez-Monteon appointed as Interim CFO, effective immediately (July 1, 2025).
- Hernandez-Monteon is an internal promotion, previously serving as VP of Finance at Genasys.
- The departure was previously disclosed in an 8-K filed on May 13, 2025.
Genasys Inc. announced the planned retirement of Chief Financial Officer Dennis D. Klahn, effective during the fiscal fourth quarter of 2025. The company is currently searching for a successor and noted there were no disagreements regarding operations or practices.
🚩 Red Flags
- Planned departure of a key C-suite officer (CFO) creates temporary leadership transition risk.
📋 Key Facts
- CFO Dennis D. Klahn announced intention to retire from all positions in Q4 2025.
- The departure is characterized as a planned retirement, not a termination for cause.
- Klahn will remain in his role until a successor is appointed to ensure an orderly transition.
- An executive search firm has been engaged to find a replacement.
- The company explicitly stated there were no disagreements with Mr. Klahn regarding operations, policies, or practices.
Genasys Inc. held its 2025 Annual Meeting of Stockholders on March 17, 2025, resulting in the election of seven directors and the approval of the company's 2025 Equity Incentive Plan. Shareholders also ratified Baker Tilly US, LLP as the independent registered public accounting firm for the upcoming fiscal year.
🚩 Red Flags
- The approval of the 2025 Equity Incentive Plan saw a significant number of 'Against' votes (6,690,236) relative to 'For' votes (8,327,901), indicating notable shareholder dissent regarding dilution or compensation structures.
📋 Key Facts
- Annual Meeting held on March 17, 2025.
- Seven directors elected: Richard H. Osgood III, Richard S. Danforth, Mark Culhane, William H. Dodd, W. Craig Fugate, R. Rimmy Malhotra, and Susan Lee Schmeiser.
- The Genasys Inc. 2025 Equity Incentive Plan was approved by stockholders.
- Initial aggregate number of shares available under the 2025 Plan is 6,000,000 (includes 5,057,285 new shares and 942,715 recycled shares from the 2015 Plan).
- Baker Tilly US, LLP was ratified as the independent registered public accounting firm for fiscal year ending September 30, 2025.
Genasys Inc. filed an 8-K to announce the release of its financial results for the fiscal quarter ended December 31, 2024. This is a routine earnings announcement filing.
📋 Key Facts
- Report date: February 11, 2025
- Reporting period: Fiscal quarter ended December 31, 2024
- The filing includes Exhibit 99.1 containing the financial results press release.
Genasys Inc. entered into a Cooperation Agreement with Nicoya Capital LLC and related entities, resulting in the expansion of its Board of Directors to include R. Rimmy Malhotra. The agreement includes standstill restrictions and voting commitments from the Investor Parties.
🚩 Red Flags
- Cooperation Agreement with 'Investor Parties' often indicates activist investor involvement or pressure to change board composition.
- Presence of standstill restrictions suggests a negotiated settlement to prevent hostile takeover or further proxy contests.
📋 Key Facts
- Entered into a Cooperation Agreement on January 14, 2025, with Nicoya Capital LLC, Nicoya Fund LLC, and Nicoya Genasys-SPV LLC.
- Board of Directors expanded from six to seven members.
- R. Rimmy Malhotra appointed to the Board and Audit Committee effective January 15, 2025.
- Investor Parties agreed to standstill restrictions and voting commitments.
- Agreement includes mutual non-disparagement provisions and procedures for director replacement.
- Mr. Malhotra will receive a $30,000 annual cash retainer and an initial grant of 5,000 RSUs.
Genasys Inc. filed an 8-K to announce its financial results for the fiscal fourth quarter and full year ended September 30, 2024. The filing serves as a formal notification that a press release containing these results was issued on December 9, 2024.
📋 Key Facts
- Reporting period: Fiscal fourth quarter and full year ended September 30, 2024.
- Filing date: December 9, 2024.
- The filing includes a press release (Exhibit 99.1) detailing financial performance.
Genasys Inc. filed an 8-K to announce the release of its financial results for the fiscal quarter ended June 30, 2024.
📋 Key Facts
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition).
- Financial results were issued via press release on August 6, 2024.
- Reporting period: Fiscal quarter ended June 30, 2024.
Genasys Inc. announced the appointment of Mark Culhane to its Board of Directors, effective July 10, 2024. Mr. Culhane will serve on both the Audit and Compensation Committees.
📋 Key Facts
- Mark Culhane appointed to the Board of Directors effective July 10, 2024.
- Term continues until the 2025 Annual Meeting of Stockholders or successor election.
- Appointed to serve on the Audit Committee and Compensation Committee.
- Annual cash compensation: $30,000 (paid quarterly).
- Annual RSU grant: up to 30,000 shares; pro-rated initial grant of 20,000 shares.
- Board has determined Mr. Culhane meets Nasdaq 'independent director' standards.
Genasys Inc. announced the resignation of Caltha Seymour from its Board of Directors, effective July 1, 2024. The departure is attributed to increasing professional demands and is not related to any disagreements with the company.
📋 Key Facts
- Caltha Seymour resigned from the Board of Directors effective July 1, 2024.
- The resignation was due to 'increasing demands of her employment'.
- The filing explicitly states the resignation is not related to any disagreements regarding company operations, policies, practices, or accounting principles.
Genasys Inc. announced the resignation of Scott L. Anchin from its Board of Directors, effective May 31, 2024. The departure is due to new employment requirements and not related to any disagreements with the company.
📋 Key Facts
- Scott L. Anchin resigned from the Board of Directors on May 20, 2024.
- The resignation becomes effective on May 31, 2024.
- Reason for departure: Requirements of new employment.
- Company explicitly states the resignation is not due to any disagreement regarding operations, policies, practices, or accounting principles.
Genasys Inc. entered into a $15 million term loan agreement with Cantor Fitzgerald Securities as administrative agent, involving significant warrants and restrictive covenants. The filing also includes the appointment of two new independent directors to the Board.
🚩 Red Flags
- Significant dilution risk due to warrants for 3.07M shares and potential 'Interest Shares' paid in stock.
- Restrictive covenants including limitations on distributions, investments, indebtedness, and asset sales.
- Lenders hold a Right of First Refusal (ROFR) on future financings, which may deter other investors.
- First-priority security interest granted to lenders covering all company assets.
📋 Key Facts
- Company borrowed $15,000,000 via a Term Loan and Security Agreement on May 13, 2024.
- Lenders were granted warrants to purchase up to 3,068,182 shares of common stock at an initial exercise price of $2.53 per share.
- Interest rate is SOFR + 5% (cash) or SOFR + 6% (if electing to pay 50% in common stock).
- The loan matures on May 13, 2026.
- Lenders have a Right of First Refusal (ROFR) on any equity or debt financings for one year following the closing.
- The loan is secured by a first-priority security interest in all company assets.
Genasys Inc. held its 2024 Annual Meeting of Stockholders on March 14, 2024. The meeting resulted in the election of five directors and the ratification of Baker Tilly US, LLP as the independent auditor.
📋 Key Facts
- Annual Meeting of Stockholders held on March 14, 2024.
- Five directors elected: Scott L. Anchin, Richard S. Danforth, Susan Lee, Richard H. Osgood III, and Caltha Seymour.
- Baker Tilly US, LLP ratified as the independent registered public accounting firm for fiscal year ending Sept 30, 2024.
- Advisory vote on executive compensation was approved by stockholders.
- Stockholders voted to hold advisory votes on executive compensation every year.
This is an amendment to a previous 8-K filing, primarily serving to provide the transcript of the company's earnings conference call for the fiscal quarter ended December 31, 2023.
📋 Key Facts
- The filing is an Amendment No. 1 to the 8-K filed on February 13, 2024.
- Includes a transcript of the earnings conference call held on February 13, 2024 (Exhibit 99.2).
- Provides financial results for the fiscal quarter ended December 31, 2023 via a press release (Exhibit 99.1).
Genasys Inc. filed an 8-K to announce the release of its financial results for the fiscal quarter ended December 31, 2023.
📋 Key Facts
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition).
- Financial results were released on February 13, 2024.
- The reported period is the fiscal quarter ended December 31, 2023.